IRIS
PINATO, David James
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.341
EU - Europa 6.323
NA - Nord America 6.011
SA - Sud America 795
AF - Africa 340
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 19.821
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.757
SG - Singapore 2.487
RU - Federazione Russa 2.467
IE - Irlanda 1.239
CN - Cina 1.169
HK - Hong Kong 1.129
BR - Brasile 593
VN - Vietnam 572
IT - Italia 542
DE - Germania 429
FR - Francia 412
SE - Svezia 369
BD - Bangladesh 217
UA - Ucraina 215
BJ - Benin 206
GB - Regno Unito 185
IN - India 171
KR - Corea 157
CA - Canada 126
FI - Finlandia 98
AT - Austria 96
MX - Messico 85
AR - Argentina 72
JP - Giappone 72
PL - Polonia 58
ES - Italia 53
ZA - Sudafrica 52
ID - Indonesia 51
NL - Olanda 46
IQ - Iraq 44
TR - Turchia 44
IR - Iran 33
CO - Colombia 32
LT - Lituania 29
MA - Marocco 26
PK - Pakistan 26
EC - Ecuador 25
PH - Filippine 25
VE - Venezuela 20
SA - Arabia Saudita 18
CL - Cile 17
CZ - Repubblica Ceca 17
UZ - Uzbekistan 15
CH - Svizzera 14
PY - Paraguay 14
BE - Belgio 13
AE - Emirati Arabi Uniti 12
OM - Oman 11
EG - Egitto 9
JO - Giordania 9
TN - Tunisia 9
JM - Giamaica 8
KE - Kenya 8
MY - Malesia 8
NP - Nepal 8
ET - Etiopia 7
IL - Israele 7
PE - Perù 7
UY - Uruguay 7
BO - Bolivia 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
KZ - Kazakistan 6
RS - Serbia 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
BG - Bulgaria 5
CR - Costa Rica 5
GT - Guatemala 5
LB - Libano 5
PS - Palestinian Territory 5
PT - Portogallo 5
SN - Senegal 5
AU - Australia 4
AZ - Azerbaigian 4
BH - Bahrain 4
HN - Honduras 4
TH - Thailandia 4
CY - Cipro 3
EU - Europa 3
HU - Ungheria 3
KG - Kirghizistan 3
LV - Lettonia 3
MN - Mongolia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
KH - Cambogia 2
LI - Liechtenstein 2
MD - Moldavia 2
NI - Nicaragua 2
RO - Romania 2
SI - Slovenia 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 19.796
Salva come PNG Salva come JPEG
Città #
Dublin 1.236
San Jose 1.145
Hong Kong 1.118
Singapore 946
Ashburn 596
Beijing 300
Moscow 296
Council Bluffs 289
Los Angeles 257
Lauterbourg 246
Cotonou 206
Ho Chi Minh City 159
Santa Clara 151
Lawrence 149
Princeton 149
Jacksonville 145
Buffalo 141
Hanoi 139
Wilmington 139
Seoul 137
New York 131
San Mateo 125
Chandler 113
Dallas 84
Falkenstein 76
São Paulo 72
Novara 67
Nuremberg 66
Orem 63
Helsinki 58
Tokyo 58
Chennai 55
Dearborn 55
Frankfurt am Main 55
Brooklyn 52
Vienna 51
Redondo Beach 48
Columbus 47
Mexico City 46
Piemonte 46
Chicago 45
Milan 44
St Louis 44
Warsaw 43
Tianjin 42
Denver 41
Munich 41
Toronto 41
London 40
Ann Arbor 38
Montreal 37
Assago 36
Haiphong 34
Johannesburg 34
Stockholm 34
Hangzhou 33
Guangzhou 32
Da Nang 30
Atlanta 29
Boardman 29
Houston 29
Phoenix 29
Turin 29
Amsterdam 27
Boston 27
Poplar 27
Manchester 25
Vercelli 25
Andover 23
Shanghai 23
Jakarta 22
Mumbai 22
Rome 22
Strasbourg 22
San Francisco 21
Shenzhen 20
Ankara 18
Bremen 18
Zanjan 16
Dhaka 14
Norwalk 14
Roubaix 14
Tashkent 13
Baghdad 12
Brasília 12
Brussels 12
Pleasantville 12
Turku 12
Belo Horizonte 11
Genoa 11
Istanbul 11
Las Vegas 11
Manila 11
New Delhi 11
Rio de Janeiro 11
Seattle 11
Woodbridge 11
Charlotte 10
City of London 10
Clifton 10
Totale 10.748
Salva come PNG Salva come JPEG
Nome #
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease 183
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 170
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 155
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 143
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study 142
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 140
L’impatto del Long COVID è stato minore nella terza ondata della pandemia rispetto alla prima ondata in una popolazione italiana di 324 pazienti. 137
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 137
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 135
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 134
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 132
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 130
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 130
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 129
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 124
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe 122
Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of patients with cancer who recovered from SARS-Cov-2 infection: results from the OnCovid registry. 121
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 120
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 119
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 118
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 117
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 116
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 114
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death 114
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries 109
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 109
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 108
Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. 107
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 106
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 105
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 104
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 104
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis 103
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 103
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 101
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 100
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 100
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study 97
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 97
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 96
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? 95
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 95
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 95
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma 95
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 94
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 94
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 94
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 92
Advanced age influences the dynamic changes in circulating C-reactive protein following injury 92
T-cell mediated responses against alpha-foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients’ survival 92
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship 91
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 91
Antibiotic therapy and outcome from immune-checkpoint inhibitors 91
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 90
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 90
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 89
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 89
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 88
A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC 87
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers 87
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 86
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 86
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 85
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 84
Acceleration of interstitial lung disease induced by raltitrexed 84
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 82
A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI) 82
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors 82
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 82
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 81
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma 81
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 81
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 81
Immunotherapies for hepatocellular carcinoma 80
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 80
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials 80
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal 79
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 79
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 79
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI) 79
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma 79
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 78
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients 78
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 78
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: Correlation with tumour phenotype and survival outcomes 77
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy 77
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 77
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 76
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 76
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis 76
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 76
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 76
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy 76
The price and value of therapeutic synergy in liver cancer 74
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) 74
Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy 74
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison 73
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 73
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 73
Back from the brink: EGFR inhibition in gastroesophageal cancer 73
Totale 9.809
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.117
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.117
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 0 0 13
2021/2022799 27 2 174 71 46 6 24 21 68 63 126 171
2022/20231.810 217 43 77 6 51 106 43 79 1.132 5 27 24
2023/20241.084 136 46 82 33 209 14 222 15 4 39 56 228
2024/20253.885 45 26 204 19 36 331 391 346 904 590 261 732
2025/202611.782 548 499 678 1.060 1.303 833 1.964 1.777 881 927 857 455
Totale 20.190